About Us

IBL-100s, partnered with Mysthera Therapeutics, is a pan-PIM kinase inhibitor program in preclinical development for the treatment of autoimmune and inflammatory diseases. IBL-202 is a first-in-class, dual PIM kinase and PI3K inhibitor in development for aggressive B-cell malignancies and T-cell lymphoma. AUM302, partnered with AUM Biosciences, is a PIM/PI3K/mTOR inhibitor in development to treat cancer.